The Antidote: Inside the World of New Pharma (76 page)

Boston Globe
,
146
,
167
,
214
,
360
,
369
–70

Boston Marathon bombing,
381
–83

Boston Red Sox,
69
,
96
,
337

brain,
198
–99,
201
,
211
,
280
,
336

CF and,
179
–80

HIV and,
19
,
32

see also
blood-brain barrier

Bristol-Myers Squibb (BMS),
143
,
183
,
287
–88,
314

HCV and,
193
,
220
,
357
,
360
,
372
–73

HIV and,
147
,
225

Brookside Capital,
287
,
331
,
343
,
352

Brown, Scott,
214
,
217
,
365

Built to Last
(Collins),
116
,
162

Burroughs Wellcome Company:

Glaxo’s merger with,
35
,
46

HIV and,
25
–27,
31
–32,
46

Bush, George W.,
61
,
143
,
167
,
176

stem cell research and,
70
,
204
–5

Bush, Vannevar,
152

Bush v. Gore
,
59

BusinessWeek
,
65
,
278
,
321

Canada,
149
,
199
,
265
,
316

cancers, cancer,
20
,
24
,
65
,
70
,
93
,
106
,
166
,
182
,
185
,
294
,
311
,
339
,
380
,
387

Gleevec and,
57
,
131
,
177

HCV and,
139
,
151
,
256
,
373

kinases and,
55
–58

Mevacor and,
15

mock AdComm and,
255

Vertex-Merck partnership and,
107
,
114

war on,
4
–5,
64
,
143
–44

Caremark-CVS,
328
,
330

Carnahan, Virginia,
179

Caron, Paul,
33
,
37
–38,
336

Cassady, Neal,
124

Celebrex,
284
,
315

Cell
,
37

CellCept,
128
,
227

cell therapy,
206

centenarians,
387
–88

Centers for Disease Control and Prevention (CDC),
213
–14,
374

Chain, Ernst,
152

Chamberlain, Wilt,
307

chemogenomics,
56
–57,
59
,
65
,
85
,
88

China,
193
,
326
–27

drug market in,
169
–70,
172
–74

Incivek and,
169
–70,
239

Thomson and,
169
–70,
173
,
290
–91,
326

Chiron Corporation,
21
,
47
–48,
101

cholesterol,
4
,
6
,
14
,
251

chronic myeloid leukemia,
57

cirrhosis,
82
,
139
,
256
,
348
,
350

Citibank, Citigroup,
222
,
308
,
332
,
344
,
380
–81

Clay, Patrick:

Incivek and,
268
–73,
275
–76

Merck and,
266
–67,
272

ClinicalTrials.gov,
268

Clinton, Bill:

dot-com crash and,
58
–59

drug prices and,
11
,
15
,
26
,
45
–46,
115

Clinton, Hillary,
11
,
15
,
26

CNBC,
193
,
216
,
237

Coakley, Martha,
214

Coles, Anthony,
100
,
107
,
130
,
184

Collins, Francis,
55
,
79
,
251
,
300

Collins, Jim,
116
,
162

combination therapies:

CF and,
250
,
295
–99,
301
–2,
363
–64,
367
–70,
381
–82

HCV and,
148
,
150
,
171
,
176
,
183
,
215
,
220
–22,
262
,
275
–76,
284
,
300
,
325
,
327
,
333
,
347
–48,
358
,
363
,
378

HIV and,
36
,
85
,
146
–47,
230
,
357

compassionate use,
305

competition,
11
,
14
,
27
,
76
,
92
,
127
,
132
,
160
,
170
,
246
,
264
,
381

Boger on,
1
–2,
12
,
366

CF and,
250
,
298
,
382

and comparisons between Vertex and Merck,
291
–92

HCV and,
34
,
37
–38,
94
,
129
,
140
,
150
–51,
172
,
186
,
194
,
200
,
207
–8,
216
–17,
220
,
223
,
226
–31,
260
–62,
286
,
307
,
324
–25,
327
,
329
,
333
,
342
,
347
,
354
,
357
,
374
,
376

HIV and,
19
,
30
,
49
,
225

Incivek and,
172
,
176
,
212
,
238
,
244
,
247
,
249
,
286
,
288
–89,
316
,
344
,
347
–49

kinases and,
53
–54,
57
,
317
–18

and mergers and acquisitions,
199
–200

in pharmaceutical industry,
1
–4

Condon, John,
167
–69,
173
,
222
,
232
,
238
–40,
289

Congress, U.S.,
163
,
202
,
213
–14,
346

financial crises and,
187
,
312

HCV and,
213
,
300

health care legislation in,
195
,
214
,
217
,
220
,
252

on pharmaceutical industry,
11
–12

Connelly, Pat,
113
–14

Conover, Damien,
311

Corporate Life Cycle Disease (CLCD),
162

correctors,
81
,
120
–21,
125
,
141
–42,
155
,
180
–81,
251
,
295
,
362
–63,
382

cortisone,
3
,
15
,
152

Cowen and Company,
212
,
328

Cozzolino, Joe,
219
,
222
,
224
,
238
,
240
–42

Crixivan,
36
,
49

Cumbo, Alexander “Bo,”
228
–30

background of,
224
–26,
229
–30,
242

CF and,
376
–77

Cozzolino’s resignation and,
241
–42

departure of,
377
–81

HIV and,
224
–26,
229
,
242

Incivek and,
224
–25,
241
–42,
262
,
264
–65,
277
,
284
,
299
–300,
316
,
347
–48,
356
,
375
–78

sales force recruited by,
224
–26,
228
,
241
–42,
376
,
379

speech of,
242
–43

cystic fibrosis (CF),
7
,
79
–82,
118
–21,
125
–27,
201
,
217
–18,
335
–38,
376
–78

comparisons between HCV and,
165
,
179
,
181
,
346
,
350
–51,
382

deaths due to,
67
,
69
,
125
,
141
,
250
,
252
,
301
–2

finances and,
67
–70,
81
,
111
,
118
,
120
,
140
–42,
145
,
182
,
281
,
297
–98,
300
–301,
304
–5,
325
,
343
–46,
353
–54,
364
–65,
378

HBS case study on,
68
–70

human testing and,
295
–98,
300
–301

Johnson case and,
252
–55,
302
–7,
363
–64,
371
–72,
381
–82

Kalydeco and,
125
,
140
–43,
146
,
153
,
177
,
179
–83,
186
,
215
,
237
,
248
–55,
295
–307,
313
,
318
,
327
,
336
,
343
–46,
353
,
358
–59,
361
–64,
367
–71,
377
–78,
380
–82,
386

lung dissections and,
125
–26

Morgan conference and,
215
,
237
–38,
360

NDAs and,
237
,
345

as orphan disease,
111
,
215
,
251
,
361

press release on,
295
–99

screening for drugs for,
67
–68

symptoms of,
79
–80,
119
–20,
238
,
248
–49,
252
–54

testing for,
79
,
252
,
302

VX-661 and,
251
,
363
–64,
372
,
381
–82

VX-809 and,
155
,
177
,
180
–81,
183
,
215
,
251
,
295
–99,
301
,
343
,
364
–65,
367
–72,
381

Cystic Fibrosis Foundation (CFF),
67
–70,
79
,
81
,
111
,
118
,
297
,
386

Kalydeco and,
140
–42,
182
,
345
,
361

Cystic Fibrosis Foundation Therapeutics (CEFT),
142

cystic fibrosis transmembrane conductance regulator (CFTR),
79
–81,
118
–21,
155
,
179
–80

combination therapies and,
250
,
295
–99,
301
–2

folding,
80
–81,
119
–21,
125
,
252
,
254
,
295
–97,
302
,
304
–6,
362
,
364
,
371

gating,
80
–81,
120
,
142
–43,
179
,
248
,
252
,
304
,
327
,
343
–44,
346
,
353
,
371
,
377

Kalydeco and,
180
,
182
,
343
–46

Daruwala, Paul,
240
,
244

David vs. Goliath,
259
–60,
291
–92

debt-ceiling crisis,
312

Dee, Lynda Marie,
266
,
275
–76

deficit reduction,
312

Deininger, Dave,
26
,
64

Dendreon,
310
–12,
324

deoxyribonucleic acid (DNA),
43

HCV and,
33
,
39
,
48

HIV and,
17
,
20
,
24
,
148

Depakote,
372

depression,
61
,
165
,
266

diabetes,
55
,
57
,
129
,
165
,
256
,
372

disease as opportunity,
84

disruptive innovation, disruptive technology,
7
,
145
,
184
,
205
–6,
333
–34

dot-com boom and crash,
55
,
58
–59,
74

Dow Jones Newswires,
238
,
319